{
  "data": [
    {
      "id": "stat_ZJH1W89QNDGEPZ0NG0HRA9AV3H",
      "url": "https://statorigin.org/stat/stat_ZJH1W89QNDGEPZ0NG0HRA9AV3H",
      "indicator": {
        "slug": "alzheimer-s-disease-innovative-drug-clinical-trial-approvals-multi-year-total",
        "name": "Alzheimer's disease innovative drug clinical trial approvals (multi-year total)",
        "definition": "Number of innovative drugs approved to initiate clinical trials for the treatment of Alzheimer's disease during the specified period."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "CN",
        "name": "China",
        "type": "country"
      },
      "period": {
        "start": "2023-01-01",
        "end": "2024-12-31",
        "type": "year"
      },
      "value": 8,
      "value_text": "eight",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "National Medical Products Administration",
        "org_short_name": "NMPA",
        "org_url": "https://english.nmpa.gov.cn",
        "org_tier": 1,
        "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs",
        "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm",
        "document_type": "press_release",
        "locator": "Measures facilitate approval of 48 first-in-class innovative drugs",
        "quote": "In the past two years, it has approved clinical trials for eight innovative drugs that could potentially treat the disease.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "National Medical Products Administration. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_ZJH1W89QNDGEPZ0NG0HRA9AV3H",
        "bibtex": "@misc{nmpa2024alzheimera9av3h,\n  author       = {{National Medical Products Administration}},\n  title        = {Measures facilitate approval of 48 first-in-class innovative drugs},\n  year         = {2024},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_ZJH1W89QNDGEPZ0NG0HRA9AV3H},\n  note         = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\\_1080286.htm. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_DCHFJWTQKEZNM8SYSXWZT57XQ7",
      "url": "https://statorigin.org/stat/stat_DCHFJWTQKEZNM8SYSXWZT57XQ7",
      "indicator": {
        "slug": "annual-net-sales-growth-guidance-at-constant-exchange-rates",
        "name": "Annual net sales growth guidance at constant exchange rates",
        "definition": "Expected percentage increase in full-year net sales at constant exchange rates."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2026-01-01",
        "end": "2026-12-31",
        "type": "year"
      },
      "value": 10,
      "value_text": "around 10%",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "forecast",
      "source": {
        "org": "Sanofi",
        "org_short_name": "Sanofi",
        "org_url": "https://www.sanofi.com",
        "org_tier": 2,
        "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded",
        "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767",
        "document_type": "press_release",
        "locator": "Guidance upgraded",
        "quote": "In 2026, sales are now expected to grow by around 10% at CER. Business EPS at CER is expected to grow slightly faster than sales.3",
        "published_date": "2026-07-30",
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_DCHFJWTQKEZNM8SYSXWZT57XQ7",
        "bibtex": "@misc{sanofi2026salest57xq7,\n  author       = {{Sanofi}},\n  title        = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_DCHFJWTQKEZNM8SYSXWZT57XQ7},\n  note         = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_9SEHGAYSGEVZP40MYK9NVXJ81A",
      "url": "https://statorigin.org/stat/stat_9SEHGAYSGEVZP40MYK9NVXJ81A",
      "indicator": {
        "slug": "antibody-drug-conjugate-approvals",
        "name": "Antibody-drug conjugate approvals",
        "definition": "Total number of antibody-drug conjugates granted regulatory marketing authorization."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "CN",
        "name": "China",
        "type": "country"
      },
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "type": "year"
      },
      "value": 3,
      "value_text": "three",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "DIA",
        "org_short_name": "DIA",
        "org_url": "https://www.diaglobal.org",
        "org_tier": 2,
        "document_title": "2025 NMPA Approvals: China Clears Record Number of New Drugs",
        "document_url": "https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/",
        "document_type": "press_release",
        "locator": "Established Modalities Maintain a Larger Presence",
        "quote": "BsAbs and peptide therapies saw four new entrants each, while ADCs, cell therapies, and fusion proteins received three approvals each.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "DIA. (2025). 2025 NMPA Approvals: China Clears Record Number of New Drugs. Retrieved September 17, 2026, from https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Via StatOrigin, https://statorigin.org/stat/stat_9SEHGAYSGEVZP40MYK9NVXJ81A",
        "bibtex": "@misc{dia2025antibodyvxj81a,\n  author       = {{DIA}},\n  title        = {2025 NMPA Approvals: China Clears Record Number of New Drugs},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_9SEHGAYSGEVZP40MYK9NVXJ81A},\n  note         = {Original source: https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_5XWSVWS6KHPM8RN9H08ECKWYJX",
      "url": "https://statorigin.org/stat/stat_5XWSVWS6KHPM8RN9H08ECKWYJX",
      "indicator": {
        "slug": "approved-class-1-innovative-drugs",
        "name": "Approved Class 1 innovative drugs",
        "definition": "Total number of Class 1 innovative drugs approved for marketing authorization."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "CN",
        "name": "China",
        "type": "country"
      },
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "type": "year"
      },
      "value": 76,
      "value_text": "76个",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "National Healthcare Security Administration",
        "org_short_name": "NHSA",
        "org_url": "https://www.nhsa.gov.cn",
        "org_tier": 1,
        "document_title": "国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况",
        "document_url": "http://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html",
        "document_type": "press_release",
        "locator": "大众新闻大众日报记者提问",
        "quote": "2025年批准上市的76个1类创新药中，既有我国本土企业原创的“全球新”，也有部分跨国企业在我国实现的“全球首发”。",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html. Via StatOrigin, https://statorigin.org/stat/stat_5XWSVWS6KHPM8RN9H08ECKWYJX",
        "bibtex": "@misc{nhsa2025approvedckwyjx,\n  author       = {{National Healthcare Security Administration}},\n  title        = {国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_5XWSVWS6KHPM8RN9H08ECKWYJX},\n  note         = {Original source: http://www.nhsa.gov.cn/art/2026/4/15/art\\_14\\_20221.html. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_KCA1ABEFQSZFJWEMVZ7Y10SVF9",
      "url": "https://statorigin.org/stat/stat_KCA1ABEFQSZFJWEMVZ7Y10SVF9",
      "indicator": {
        "slug": "approved-class-1-innovative-drugs-half-year",
        "name": "Approved Class 1 innovative drugs (half year)",
        "definition": "Total number of Class 1 innovative drugs approved for marketing authorization."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "CN",
        "name": "China",
        "type": "country"
      },
      "period": {
        "start": "2026-01-01",
        "end": "2026-06-30",
        "type": "point"
      },
      "value": 38,
      "value_text": "38个",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "National Healthcare Security Administration",
        "org_short_name": "NHSA",
        "org_url": "https://www.nhsa.gov.cn",
        "org_tier": 1,
        "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元",
        "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html",
        "document_type": "press_release",
        "locator": "今年38个1类创新药已获批上市 11款新靶点、新机制药均为国产",
        "quote": "记者今天从国家药监局获悉，最新统计显示，今年上半年我国批准38个1类创新药上市。",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "National Healthcare Security Administration. (2026). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_KCA1ABEFQSZFJWEMVZ7Y10SVF9",
        "bibtex": "@misc{nhsa2026approved10svf9,\n  author       = {{National Healthcare Security Administration}},\n  title        = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_KCA1ABEFQSZFJWEMVZ7Y10SVF9},\n  note         = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_1WGYBP9BMEKJBY30RP8KX65K3G",
      "url": "https://statorigin.org/stat/stat_1WGYBP9BMEKJBY30RP8KX65K3G",
      "indicator": {
        "slug": "approved-drug-marketing-registration-applications-half-year",
        "name": "Approved drug marketing registration applications (half year)",
        "definition": "Total number of drug marketing registration applications approved by the regulatory authority."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "CN",
        "name": "China",
        "type": "country"
      },
      "period": {
        "start": "2026-01-01",
        "end": "2026-06-30",
        "type": "point"
      },
      "value": 2318,
      "value_text": "2318件",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "National Healthcare Security Administration",
        "org_short_name": "NHSA",
        "org_url": "https://www.nhsa.gov.cn",
        "org_tier": 1,
        "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元",
        "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html",
        "document_type": "press_release",
        "locator": "今年38个1类创新药已获批上市 11款新靶点、新机制药均为国产",
        "quote": "国家药监局药品注册管理司副司长蓝恭涛表示，截至6月底，国家药监局今年共批准药品上市注册申请2318件，其中“全球新”创新药38个，包括20个化学药品，17个生物制品和1个中药。",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "National Healthcare Security Administration. (2026). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_1WGYBP9BMEKJBY30RP8KX65K3G",
        "bibtex": "@misc{nhsa2026approvedx65k3g,\n  author       = {{National Healthcare Security Administration}},\n  title        = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_1WGYBP9BMEKJBY30RP8KX65K3G},\n  note         = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_MBM4FPC6Q63D53V4H7947N7R0N",
      "url": "https://statorigin.org/stat/stat_MBM4FPC6Q63D53V4H7947N7R0N",
      "indicator": {
        "slug": "approved-immunotherapy-drugs-multi-year-total",
        "name": "Approved immunotherapy drugs (multi-year total)",
        "definition": "Cumulative number of immunotherapy pharmaceutical products authorized for therapeutic use."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "US",
        "name": "United States",
        "type": "country"
      },
      "period": {
        "start": "2010-01-01",
        "end": "2025-12-31",
        "type": "year"
      },
      "value": 30,
      "value_text": "over 30",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "PhRMA",
        "org_short_name": "PhRMA",
        "org_url": "https://phrma.org",
        "org_tier": 2,
        "document_title": "Research & Development",
        "document_url": "https://phrma.org/policy-issues/research-development",
        "document_type": "press_release",
        "locator": "Revolutionizing Cancer Care with Immunotherapy",
        "quote": "Since 2010, over 30 immunotherapy drugs have been approved to treat 25 types of cancer.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "PhRMA. (2025). Research & Development. Retrieved September 17, 2026, from https://phrma.org/policy-issues/research-development. Via StatOrigin, https://statorigin.org/stat/stat_MBM4FPC6Q63D53V4H7947N7R0N",
        "bibtex": "@misc{phrma2025approved7n7r0n,\n  author       = {{PhRMA}},\n  title        = {Research \\& Development},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_MBM4FPC6Q63D53V4H7947N7R0N},\n  note         = {Original source: https://phrma.org/policy-issues/research-development. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_0SEXJ7ZASPFSZTGZC1KYQDWKA4",
      "url": "https://statorigin.org/stat/stat_0SEXJ7ZASPFSZTGZC1KYQDWKA4",
      "indicator": {
        "slug": "approved-innovative-drugs-designated-as-breakthrough-therapies",
        "name": "Approved innovative drugs designated as breakthrough therapies",
        "definition": "Number of approved innovative drugs that previously received breakthrough therapy designation during development."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "CN",
        "name": "China",
        "type": "country"
      },
      "period": {
        "start": "2024-01-01",
        "end": "2024-12-31",
        "type": "year"
      },
      "value": 13,
      "value_text": "13",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "State Council of China",
        "org_short_name": "State Council",
        "org_url": "https://www.gov.cn",
        "org_tier": 1,
        "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs",
        "document_url": "https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html",
        "document_type": "press_release",
        "locator": "Measures facilitate approval of 48 first-in-class innovative drugs",
        "quote": "Among them, 17 received market approval through a priority review pathway, 11 gained conditional market approval and 13 were included in breakthrough therapy programs during clinical trials, according to the report from the administration's drug evaluation center.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "State Council of China. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Via StatOrigin, https://statorigin.org/stat/stat_0SEXJ7ZASPFSZTGZC1KYQDWKA4",
        "bibtex": "@misc{statecouncil2024approvedqdwka4,\n  author       = {{State Council of China}},\n  title        = {Measures facilitate approval of 48 first-in-class innovative drugs},\n  year         = {2024},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_0SEXJ7ZASPFSZTGZC1KYQDWKA4},\n  note         = {Original source: https://english.www.gov.cn/news/202503/20/content\\_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_N9A1J88TV8X7J63HZ4MEQ9G5C2",
      "url": "https://statorigin.org/stat/stat_N9A1J88TV8X7J63HZ4MEQ9G5C2",
      "indicator": {
        "slug": "approved-innovative-drugs-designated-as-breakthrough-therapies",
        "name": "Approved innovative drugs designated as breakthrough therapies",
        "definition": "Number of approved innovative drugs that previously received breakthrough therapy designation during development."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "CN",
        "name": "China",
        "type": "country"
      },
      "period": {
        "start": "2024-01-01",
        "end": "2024-12-31",
        "type": "year"
      },
      "value": 13,
      "value_text": "13",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "National Medical Products Administration",
        "org_short_name": "NMPA",
        "org_url": "https://english.nmpa.gov.cn",
        "org_tier": 1,
        "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs",
        "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm",
        "document_type": "press_release",
        "locator": "Measures facilitate approval of 48 first-in-class innovative drugs",
        "quote": "Among them, 17 received market approval through a priority review pathway, 11 gained conditional market approval and 13 were included in breakthrough therapy programs during clinical trials, according to the report from the administration's drug evaluation center.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "National Medical Products Administration. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_N9A1J88TV8X7J63HZ4MEQ9G5C2",
        "bibtex": "@misc{nmpa2024approvedq9g5c2,\n  author       = {{National Medical Products Administration}},\n  title        = {Measures facilitate approval of 48 first-in-class innovative drugs},\n  year         = {2024},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_N9A1J88TV8X7J63HZ4MEQ9G5C2},\n  note         = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\\_1080286.htm. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_H8FD1RAF0HRJDA674FRB5MNFWX",
      "url": "https://statorigin.org/stat/stat_H8FD1RAF0HRJDA674FRB5MNFWX",
      "indicator": {
        "slug": "approved-innovative-drugs-growth-rate",
        "name": "Approved innovative drugs growth rate",
        "definition": "Year-on-year percentage growth rate of innovative drugs approved for marketing."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "CN",
        "name": "China",
        "type": "country"
      },
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "type": "year"
      },
      "value": 58.3,
      "value_text": "58.3%",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "Ministry of Commerce of China",
        "org_short_name": "MOFCOM",
        "org_url": "https://www.mofcom.gov.cn",
        "org_tier": 1,
        "document_title": "2025年我国批准创新药76个 对外授权超千亿美元",
        "document_url": "https://tradeinservices.mofcom.gov.cn/article/hyly/zyy/zyyfwbmdt/202601/180991.html",
        "document_type": "press_release",
        "locator": "2025年我国批准创新药76个 对外授权超千亿美元",
        "quote": "从国家药品监督管理局获悉，2025年我国创新药审评审批取得历史性突破，全年共批准上市创新药76个，较2024年的48个大幅增长58.3%，创历史新高；同时，数据显示，中国创新药对外授权（BD）交易总金额达1356.55亿美元，交易数量达157笔，双双刷新纪录。",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "Ministry of Commerce of China. (2025). 2025年我国批准创新药76个 对外授权超千亿美元. Retrieved September 17, 2026, from https://tradeinservices.mofcom.gov.cn/article/hyly/zyy/zyyfwbmdt/202601/180991.html. Via StatOrigin, https://statorigin.org/stat/stat_H8FD1RAF0HRJDA674FRB5MNFWX",
        "bibtex": "@misc{mofcom2025approved5mnfwx,\n  author       = {{Ministry of Commerce of China}},\n  title        = {2025年我国批准创新药76个 对外授权超千亿美元},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_H8FD1RAF0HRJDA674FRB5MNFWX},\n  note         = {Original source: https://tradeinservices.mofcom.gov.cn/article/hyly/zyy/zyyfwbmdt/202601/180991.html. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_VXVARPPSBWC8A6ZCKDBPQNRYD3",
      "url": "https://statorigin.org/stat/stat_VXVARPPSBWC8A6ZCKDBPQNRYD3",
      "indicator": {
        "slug": "approved-innovative-drugs-with-new-targets-or-mechanisms",
        "name": "Approved innovative drugs with new targets or mechanisms",
        "definition": "Total number of innovative drugs with novel biological targets or mechanisms of action approved for marketing."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "CN",
        "name": "China",
        "type": "country"
      },
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "type": "year"
      },
      "value": 11,
      "value_text": "11个",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "National Healthcare Security Administration",
        "org_short_name": "NHSA",
        "org_url": "https://www.nhsa.gov.cn",
        "org_tier": 1,
        "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元",
        "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html",
        "document_type": "press_release",
        "locator": "今年38个1类创新药已获批上市 11款新靶点、新机制药均为国产",
        "quote": "据介绍，今年上半年批准上市的38个创新药中，有11个是新靶点、新机制的药品，并且均为自主研发的国产创新药；而2025年我国批准的11个新靶点、新机制药品中，4个是国产创新药，占比不到一半。",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_VXVARPPSBWC8A6ZCKDBPQNRYD3",
        "bibtex": "@misc{nhsa2025approvedqnryd3,\n  author       = {{National Healthcare Security Administration}},\n  title        = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_VXVARPPSBWC8A6ZCKDBPQNRYD3},\n  note         = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_RYGSZH3DKE8N9CQ1G9B03GV1VA",
      "url": "https://statorigin.org/stat/stat_RYGSZH3DKE8N9CQ1G9B03GV1VA",
      "indicator": {
        "slug": "approved-innovative-drugs-with-new-targets-or-mechanisms-half-year",
        "name": "Approved innovative drugs with new targets or mechanisms (half year)",
        "definition": "Total number of innovative drugs with novel biological targets or mechanisms of action approved for marketing."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "CN",
        "name": "China",
        "type": "country"
      },
      "period": {
        "start": "2026-01-01",
        "end": "2026-06-30",
        "type": "point"
      },
      "value": 11,
      "value_text": "11个",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "National Healthcare Security Administration",
        "org_short_name": "NHSA",
        "org_url": "https://www.nhsa.gov.cn",
        "org_tier": 1,
        "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元",
        "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html",
        "document_type": "press_release",
        "locator": "今年38个1类创新药已获批上市 11款新靶点、新机制药均为国产",
        "quote": "据介绍，今年上半年批准上市的38个创新药中，有11个是新靶点、新机制的药品，并且均为自主研发的国产创新药；而2025年我国批准的11个新靶点、新机制药品中，4个是国产创新药，占比不到一半。",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "National Healthcare Security Administration. (2026). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_RYGSZH3DKE8N9CQ1G9B03GV1VA",
        "bibtex": "@misc{nhsa2026approved3gv1va,\n  author       = {{National Healthcare Security Administration}},\n  title        = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_RYGSZH3DKE8N9CQ1G9B03GV1VA},\n  note         = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_T1T4DYFSWBGNW2SKA622VN2Y2D",
      "url": "https://statorigin.org/stat/stat_T1T4DYFSWBGNW2SKA622VN2Y2D",
      "indicator": {
        "slug": "approved-novel-drugs-in-breakthrough-therapy-programs",
        "name": "Approved novel drugs in breakthrough therapy programs",
        "definition": "Number of approved novel drugs that participated in breakthrough therapy programs during clinical development."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "CN",
        "name": "China",
        "type": "country"
      },
      "period": {
        "start": "2024-01-01",
        "end": "2024-12-31",
        "type": "year"
      },
      "value": 13,
      "value_text": "13",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "National Medical Products Administration",
        "org_short_name": "NMPA",
        "org_url": "https://english.nmpa.gov.cn",
        "org_tier": 1,
        "document_title": "China approves 48 innovative drugs in 2024",
        "document_url": "https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm",
        "document_type": "press_release",
        "locator": "China approves 48 innovative drugs in 2024",
        "quote": "The report stated that 17 among the 48 novel drugs received market approval through a priority review pathway, 11 gained conditional market approval and 13 were included in breakthrough therapy programs during clinical trials.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "National Medical Products Administration. (2024). China approves 48 innovative drugs in 2024. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm. Via StatOrigin, https://statorigin.org/stat/stat_T1T4DYFSWBGNW2SKA622VN2Y2D",
        "bibtex": "@misc{nmpa2024approvedvn2y2d,\n  author       = {{National Medical Products Administration}},\n  title        = {China approves 48 innovative drugs in 2024},\n  year         = {2024},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_T1T4DYFSWBGNW2SKA622VN2Y2D},\n  note         = {Original source: https://english.nmpa.gov.cn/2025-03/19/c\\_1079532.htm. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_FRE7CHVKGNJN3911RBNGBJF45S",
      "url": "https://statorigin.org/stat/stat_FRE7CHVKGNJN3911RBNGBJF45S",
      "indicator": {
        "slug": "average-cost-to-develop-a-new-medicine",
        "name": "Average cost to develop a new medicine",
        "definition": "Estimated average capitalized expenditure required to discover, clinically test, and license a new pharmaceutical product."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "type": "point"
      },
      "value": 2.6,
      "value_text": "$2.6 billion",
      "unit": "USD",
      "currency": "USD",
      "scale": "billion",
      "value_type": "estimate",
      "source": {
        "org": "PhRMA",
        "org_short_name": "PhRMA",
        "org_url": "https://phrma.org",
        "org_tier": 2,
        "document_title": "Research & Development",
        "document_url": "https://phrma.org/policy-issues/research-development",
        "document_type": "press_release",
        "locator": "Progress toward New Medicines and Vaccines",
        "quote": "On average, it takes 10-15 years and costs $2.6 billion to develop one new medicine, including the cost of the many failures.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "PhRMA. (2025). Research & Development. Retrieved September 17, 2026, from https://phrma.org/policy-issues/research-development. Via StatOrigin, https://statorigin.org/stat/stat_FRE7CHVKGNJN3911RBNGBJF45S",
        "bibtex": "@misc{phrma2025averagebjf45s,\n  author       = {{PhRMA}},\n  title        = {Research \\& Development},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_FRE7CHVKGNJN3911RBNGBJF45S},\n  note         = {Original source: https://phrma.org/policy-issues/research-development. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_YBYHGK0ZP18XJ17TE3M39MKSD4",
      "url": "https://statorigin.org/stat/stat_YBYHGK0ZP18XJ17TE3M39MKSD4",
      "indicator": {
        "slug": "beneficiaries-of-negotiated-reimbursement-drugs",
        "name": "Beneficiaries of negotiated reimbursement drugs",
        "definition": "Cumulative count of patient visits or individuals benefiting from price-negotiated reimbursement medicines."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "CN",
        "name": "China",
        "type": "country"
      },
      "period": {
        "start": "2018-01-01",
        "end": "2024-10-31",
        "type": "point"
      },
      "value": 830,
      "value_text": "8.3亿人次",
      "unit": "count",
      "currency": null,
      "scale": "million",
      "value_type": "actual",
      "source": {
        "org": "National Healthcare Security Administration",
        "org_short_name": "NHSA",
        "org_url": "https://www.nhsa.gov.cn",
        "org_tier": 1,
        "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录",
        "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html",
        "document_type": "press_release",
        "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录",
        "quote": "截至2024年10月底，协议期内谈判药品累计受益8.3亿人次，累计为患者减负超8800亿元，充分彰显党和政府对人民健康福祉的高度关切。",
        "published_date": "2024-11-28",
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_YBYHGK0ZP18XJ17TE3M39MKSD4",
        "bibtex": "@misc{nhsa2024beneficiaries9mksd4,\n  author       = {{National Healthcare Security Administration}},\n  title        = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n  year         = {2024},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_YBYHGK0ZP18XJ17TE3M39MKSD4},\n  note         = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_R7VPZ3Y198V455WDHSD3E3W11N",
      "url": "https://statorigin.org/stat/stat_R7VPZ3Y198V455WDHSD3E3W11N",
      "indicator": {
        "slug": "beneficiaries-of-negotiated-reimbursement-drugs",
        "name": "Beneficiaries of negotiated reimbursement drugs",
        "definition": "Cumulative count of patient visits or individuals benefiting from price-negotiated reimbursement medicines."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "CN",
        "name": "China",
        "type": "country"
      },
      "period": {
        "start": "2018-01-01",
        "end": "2024-10-31",
        "type": "point"
      },
      "value": 830,
      "value_text": "8.3亿人次",
      "unit": "count",
      "currency": null,
      "scale": "million",
      "value_type": "actual",
      "source": {
        "org": "State Council of China",
        "org_short_name": "State Council",
        "org_url": "https://www.gov.cn",
        "org_tier": 1,
        "document_title": "2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网",
        "document_url": "https://www.gov.cn/zhengce/202411/content_6989980.htm",
        "document_type": "press_release",
        "locator": "7年累计将835种药品新增进入目录",
        "quote": "截至2024年10月底，医保基金为协议期内谈判药品支付累计超过3500亿元，惠及患者8.3亿人次。",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "State Council of China. (2024). 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网. Retrieved September 17, 2026, from https://www.gov.cn/zhengce/202411/content_6989980.htm. Via StatOrigin, https://statorigin.org/stat/stat_R7VPZ3Y198V455WDHSD3E3W11N",
        "bibtex": "@misc{statecouncil2024beneficiariese3w11n,\n  author       = {{State Council of China}},\n  title        = {2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药\\_政策解读\\_中国政府网},\n  year         = {2024},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_R7VPZ3Y198V455WDHSD3E3W11N},\n  note         = {Original source: https://www.gov.cn/zhengce/202411/content\\_6989980.htm. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_FXX75R17XTD8EC3NEN7WD7C6RW",
      "url": "https://statorigin.org/stat/stat_FXX75R17XTD8EC3NEN7WD7C6RW",
      "indicator": {
        "slug": "bioequivalence-trials",
        "name": "Bioequivalence trials",
        "definition": "Total number of registered bioequivalence trials."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "CN",
        "name": "China",
        "type": "country"
      },
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "type": "year"
      },
      "value": 2218,
      "value_text": "2218项",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "National Healthcare Security Administration",
        "org_short_name": "NHSA",
        "org_url": "https://www.nhsa.gov.cn",
        "org_tier": 1,
        "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升",
        "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html",
        "document_type": "press_release",
        "locator": "试验包括新药临床试验和生物等效性试验",
        "quote": "其中，新药临床试验2997项，占比57.5%，同比增长18%；生物等效性试验2218项，占比42.5%。",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_FXX75R17XTD8EC3NEN7WD7C6RW",
        "bibtex": "@misc{nhsa2025bioequivalenced7c6rw,\n  author       = {{National Healthcare Security Administration}},\n  title        = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_FXX75R17XTD8EC3NEN7WD7C6RW},\n  note         = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_HEBDQ5W4X21WJNF05KTYPFNKZQ",
      "url": "https://statorigin.org/stat/stat_HEBDQ5W4X21WJNF05KTYPFNKZQ",
      "indicator": {
        "slug": "bioequivalence-trials-share",
        "name": "Bioequivalence trials share",
        "definition": "Share of bioequivalence trials in total registered clinical trials."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "CN",
        "name": "China",
        "type": "country"
      },
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "type": "year"
      },
      "value": 42.5,
      "value_text": "42.5%",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "National Healthcare Security Administration",
        "org_short_name": "NHSA",
        "org_url": "https://www.nhsa.gov.cn",
        "org_tier": 1,
        "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升",
        "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html",
        "document_type": "press_release",
        "locator": "试验包括新药临床试验和生物等效性试验",
        "quote": "其中，新药临床试验2997项，占比57.5%，同比增长18%；生物等效性试验2218项，占比42.5%。",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_HEBDQ5W4X21WJNF05KTYPFNKZQ",
        "bibtex": "@misc{nhsa2025bioequivalencepfnkzq,\n  author       = {{National Healthcare Security Administration}},\n  title        = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_HEBDQ5W4X21WJNF05KTYPFNKZQ},\n  note         = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_JM8R59GFDJR6JR50N6ESCFDKCW",
      "url": "https://statorigin.org/stat/stat_JM8R59GFDJR6JR50N6ESCFDKCW",
      "indicator": {
        "slug": "biologic-therapy-approvals",
        "name": "Biologic therapy approvals",
        "definition": "Total number of biological therapeutics granted regulatory marketing approval."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "CN",
        "name": "China",
        "type": "country"
      },
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "type": "year"
      },
      "value": 40,
      "value_text": "40",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "DIA",
        "org_short_name": "DIA",
        "org_url": "https://www.diaglobal.org",
        "org_tier": 2,
        "document_title": "2025 NMPA Approvals: China Clears Record Number of New Drugs",
        "document_url": "https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/",
        "document_type": "press_release",
        "locator": "2025 NMPA Approvals: China Clears Record Number of New Drugs",
        "quote": "These include 80 conventional medicines such as small molecules, peptides, and nucleic acids, as well as 40 biologic therapies such as monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), and cell therapies.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "DIA. (2025). 2025 NMPA Approvals: China Clears Record Number of New Drugs. Retrieved September 17, 2026, from https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Via StatOrigin, https://statorigin.org/stat/stat_JM8R59GFDJR6JR50N6ESCFDKCW",
        "bibtex": "@misc{dia2025biologiccfdkcw,\n  author       = {{DIA}},\n  title        = {2025 NMPA Approvals: China Clears Record Number of New Drugs},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_JM8R59GFDJR6JR50N6ESCFDKCW},\n  note         = {Original source: https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_P5RVAZ88DTFW4FMEP5VTP07QF2",
      "url": "https://statorigin.org/stat/stat_P5RVAZ88DTFW4FMEP5VTP07QF2",
      "indicator": {
        "slug": "biopharma-biotech-and-ai-companies-count",
        "name": "Biopharma, biotech and AI companies count",
        "definition": "Total count of operating biopharmaceutical, biotechnology, and artificial intelligence companies located within a cluster."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "GB",
        "name": "United Kingdom",
        "type": "country"
      },
      "period": {
        "start": "2026-07-28",
        "end": "2026-07-28",
        "type": "point"
      },
      "value": 470,
      "value_text": "470",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "GSK",
        "org_short_name": "GSK",
        "org_url": "https://www.gsk.com",
        "org_tier": 2,
        "document_title": "GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK",
        "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-new-flagship-rd-centre-on-cambridge-biomedical-campus-uk/",
        "document_type": "press_release",
        "locator": "GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK",
        "quote": "More than 1 million patients are treated on the campus every year, and over 470 biopharma/ biotech and AI companies are located there.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "GSK. (2026). GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-new-flagship-rd-centre-on-cambridge-biomedical-campus-uk/. Via StatOrigin, https://statorigin.org/stat/stat_P5RVAZ88DTFW4FMEP5VTP07QF2",
        "bibtex": "@misc{gsk2026biopharmap07qf2,\n  author       = {{GSK}},\n  title        = {GSK to establish new flagship R\\&D centre on Cambridge Biomedical Campus, UK},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_P5RVAZ88DTFW4FMEP5VTP07QF2},\n  note         = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-new-flagship-rd-centre-on-cambridge-biomedical-campus-uk/. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_AA927K4APEG4WA76H7YWADD4EW",
      "url": "https://statorigin.org/stat/stat_AA927K4APEG4WA76H7YWADD4EW",
      "indicator": {
        "slug": "biopharmaceutical-r-d-expenditure-multi-year-total",
        "name": "Biopharmaceutical R&D expenditure (multi-year total)",
        "definition": "Total capital expenditure invested by biopharmaceutical companies into research and development of new medicines."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "US",
        "name": "United States",
        "type": "country"
      },
      "period": {
        "start": "2015-01-01",
        "end": "2024-12-31",
        "type": "year"
      },
      "value": 900,
      "value_text": "over $900 billion",
      "unit": "USD",
      "currency": "USD",
      "scale": "billion",
      "value_type": "actual",
      "source": {
        "org": "PhRMA",
        "org_short_name": "PhRMA",
        "org_url": "https://phrma.org",
        "org_tier": 2,
        "document_title": "Research & Development",
        "document_url": "https://phrma.org/policy-issues/research-development",
        "document_type": "press_release",
        "locator": "Policy Framework",
        "quote": "Over the past decade, PhRMA member companies have invested over $900 billion in developing new treatments and cures, yielding groundbreaking results.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "PhRMA. (2024). Research & Development. Retrieved September 17, 2026, from https://phrma.org/policy-issues/research-development. Via StatOrigin, https://statorigin.org/stat/stat_AA927K4APEG4WA76H7YWADD4EW",
        "bibtex": "@misc{phrma2024biopharmaceuticaladd4ew,\n  author       = {{PhRMA}},\n  title        = {Research \\& Development},\n  year         = {2024},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_AA927K4APEG4WA76H7YWADD4EW},\n  note         = {Original source: https://phrma.org/policy-issues/research-development. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_GJ0HSPRESAY30Y07N4XMBZF857",
      "url": "https://statorigin.org/stat/stat_GJ0HSPRESAY30Y07N4XMBZF857",
      "indicator": {
        "slug": "biosimilar-biological-product-approvals",
        "name": "Biosimilar biological product approvals",
        "definition": "Number of biosimilar biological products approved during the period."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "US",
        "name": "United States",
        "type": "country"
      },
      "period": {
        "start": "2024-01-01",
        "end": "2024-12-31",
        "type": "year"
      },
      "value": 18,
      "value_text": "18",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "U.S. Food and Drug Administration",
        "org_short_name": "FDA",
        "org_url": "https://www.fda.gov",
        "org_tier": 1,
        "document_title": "CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024",
        "document_url": "https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024",
        "document_type": "press_release",
        "locator": "A Record Year for Biosimilar Approvals",
        "quote": "This milestone is due to CDER approving in 2024 a record total of 18 biosimilars for 8 reference products, more than any previous year.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "U.S. Food and Drug Administration. (2024). CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024. Retrieved September 17, 2026, from https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Via StatOrigin, https://statorigin.org/stat/stat_GJ0HSPRESAY30Y07N4XMBZF857",
        "bibtex": "@misc{fda2024biosimilarbzf857,\n  author       = {{U.S. Food and Drug Administration}},\n  title        = {CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024},\n  year         = {2024},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_GJ0HSPRESAY30Y07N4XMBZF857},\n  note         = {Original source: https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_VTRXBDTB1NEFN7JEV4E02EV9S9",
      "url": "https://statorigin.org/stat/stat_VTRXBDTB1NEFN7JEV4E02EV9S9",
      "indicator": {
        "slug": "bispecific-antibody-approvals",
        "name": "Bispecific antibody approvals",
        "definition": "Total number of bispecific antibody therapies authorized for commercial marketing."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "CN",
        "name": "China",
        "type": "country"
      },
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "type": "year"
      },
      "value": 4,
      "value_text": "four",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "DIA",
        "org_short_name": "DIA",
        "org_url": "https://www.diaglobal.org",
        "org_tier": 2,
        "document_title": "2025 NMPA Approvals: China Clears Record Number of New Drugs",
        "document_url": "https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/",
        "document_type": "press_release",
        "locator": "Established Modalities Maintain a Larger Presence",
        "quote": "BsAbs and peptide therapies saw four new entrants each, while ADCs, cell therapies, and fusion proteins received three approvals each.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "DIA. (2025). 2025 NMPA Approvals: China Clears Record Number of New Drugs. Retrieved September 17, 2026, from https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Via StatOrigin, https://statorigin.org/stat/stat_VTRXBDTB1NEFN7JEV4E02EV9S9",
        "bibtex": "@misc{dia2025bispecific2ev9s9,\n  author       = {{DIA}},\n  title        = {2025 NMPA Approvals: China Clears Record Number of New Drugs},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_VTRXBDTB1NEFN7JEV4E02EV9S9},\n  note         = {Original source: https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_NRSYQY2AXZDY94AMEFRD5DCGKY",
      "url": "https://statorigin.org/stat/stat_NRSYQY2AXZDY94AMEFRD5DCGKY",
      "indicator": {
        "slug": "botanical-drug-products-approved-as-prescription-drugs",
        "name": "Botanical drug products approved as prescription drugs",
        "definition": "Cumulative number of botanical drug products approved for marketing as prescription drugs through new drug applications."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "US",
        "name": "United States",
        "type": "country"
      },
      "period": {
        "start": "2026-09-03",
        "end": "2026-09-03",
        "type": "point"
      },
      "value": 4,
      "value_text": "four",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "U.S. Food and Drug Administration",
        "org_short_name": "FDA",
        "org_url": "https://www.fda.gov",
        "org_tier": 1,
        "document_title": "FDA Seeks Public Input to Advance Development of Botanical Drug Products",
        "document_url": "https://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-advance-development-botanical-drug-products",
        "document_type": "press_release",
        "locator": "FDA Seeks Public Input to Advance Development of Botanical Drug Products",
        "quote": "To date, four botanical products have been approved for marketing as prescription drugs through the FDA’s new drug application and biologics license application pathways.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "U.S. Food and Drug Administration. (2026). FDA Seeks Public Input to Advance Development of Botanical Drug Products. Retrieved September 17, 2026, from https://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-advance-development-botanical-drug-products. Via StatOrigin, https://statorigin.org/stat/stat_NRSYQY2AXZDY94AMEFRD5DCGKY",
        "bibtex": "@misc{fda2026botanical5dcgky,\n  author       = {{U.S. Food and Drug Administration}},\n  title        = {FDA Seeks Public Input to Advance Development of Botanical Drug Products},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_NRSYQY2AXZDY94AMEFRD5DCGKY},\n  note         = {Original source: https://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-advance-development-botanical-drug-products. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_GMYPTHCR25PSS2A2G385G7T53M",
      "url": "https://statorigin.org/stat/stat_GMYPTHCR25PSS2A2G385G7T53M",
      "indicator": {
        "slug": "branded-medicines-sales-clawback-cap",
        "name": "Branded medicines sales clawback cap",
        "definition": "Statutory or agreed ceiling on revenue clawback rates applied to branded prescription medicine sales."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "GB",
        "name": "United Kingdom",
        "type": "country"
      },
      "period": {
        "start": "2026-09-08",
        "end": "2026-09-08",
        "type": "point"
      },
      "value": 15,
      "value_text": "15 per cent",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "Association of the British Pharmaceutical Industry",
        "org_short_name": "ABPI",
        "org_url": "https://www.abpi.org.uk",
        "org_tier": 2,
        "document_title": "Green shoots for UK pharma investment, but delivery will decide whether they take root",
        "document_url": "https://www.abpi.org.uk/media/news/2026/august/green-shoots-for-uk-pharma-investment-but-delivery-will-decide-whether-they-take-root/",
        "document_type": "press_release",
        "locator": "UK competitive weaknesses",
        "quote": "Despite a new 15 per cent cap on branded medicines sales clawback rates, the UK's rate on newer medicines remains higher than every other comparator country in the analysis, several of which operate no clawback system at all.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "Association of the British Pharmaceutical Industry. (2026). Green shoots for UK pharma investment, but delivery will decide whether they take root. Retrieved September 17, 2026, from https://www.abpi.org.uk/media/news/2026/august/green-shoots-for-uk-pharma-investment-but-delivery-will-decide-whether-they-take-root/. Via StatOrigin, https://statorigin.org/stat/stat_GMYPTHCR25PSS2A2G385G7T53M",
        "bibtex": "@misc{abpi2026brandedg7t53m,\n  author       = {{Association of the British Pharmaceutical Industry}},\n  title        = {Green shoots for UK pharma investment, but delivery will decide whether they take root},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_GMYPTHCR25PSS2A2G385G7T53M},\n  note         = {Original source: https://www.abpi.org.uk/media/news/2026/august/green-shoots-for-uk-pharma-investment-but-delivery-will-decide-whether-they-take-root/. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_EVH61V5CNVGR3ADB2EDGQSS2AM",
      "url": "https://statorigin.org/stat/stat_EVH61V5CNVGR3ADB2EDGQSS2AM",
      "indicator": {
        "slug": "breast-cancer-drug-approvals",
        "name": "Breast cancer drug approvals",
        "definition": "Number of new pharmaceutical therapies approved for breast cancer indications."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "CN",
        "name": "China",
        "type": "country"
      },
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "type": "year"
      },
      "value": 9,
      "value_text": "nine",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "DIA",
        "org_short_name": "DIA",
        "org_url": "https://www.diaglobal.org",
        "org_tier": 2,
        "document_title": "2025 NMPA Approvals: China Clears Record Number of New Drugs",
        "document_url": "https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/",
        "document_type": "press_release",
        "locator": "The Cancer Sector Continues to Attract the Most Players",
        "quote": "Breast cancer was the most active area with a total of nine new entrants, including the PI3Kα inhibitor inavolisib, the AKT inhibitor capivasertib, the TROP2- and HER2-targeted ADCs datopotamab deruxtecan and trastuzumab botidotin respectively, as well as multiple CDK inhibitors, namely bireociclib, lerociclib, tibremciclib, fovinaciclib, and culmerciclib.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "DIA. (2025). 2025 NMPA Approvals: China Clears Record Number of New Drugs. Retrieved September 17, 2026, from https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Via StatOrigin, https://statorigin.org/stat/stat_EVH61V5CNVGR3ADB2EDGQSS2AM",
        "bibtex": "@misc{dia2025breastqss2am,\n  author       = {{DIA}},\n  title        = {2025 NMPA Approvals: China Clears Record Number of New Drugs},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_EVH61V5CNVGR3ADB2EDGQSS2AM},\n  note         = {Original source: https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_SY02QGKVB4X94AC70CRT9QZ2PE",
      "url": "https://statorigin.org/stat/stat_SY02QGKVB4X94AC70CRT9QZ2PE",
      "indicator": {
        "slug": "business-eps-growth-at-constant-exchange-rates",
        "name": "Business EPS growth at constant exchange rates",
        "definition": "Percentage growth in non-IFRS business earnings per share calculated at constant exchange rates."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2026-04-01",
        "end": "2026-06-30",
        "type": "quarter"
      },
      "value": 33.3,
      "value_text": "33.3%",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "Sanofi",
        "org_short_name": "Sanofi",
        "org_url": "https://www.sanofi.com",
        "org_tier": 2,
        "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded",
        "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767",
        "document_type": "press_release",
        "locator": "Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded",
        "quote": "Business EPS was €2.09, up by 33.3% at CER; 31.4% at actual exchange rates; IFRS EPS €0.29",
        "published_date": "2026-07-30",
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_SY02QGKVB4X94AC70CRT9QZ2PE",
        "bibtex": "@misc{sanofi2026business9qz2pe,\n  author       = {{Sanofi}},\n  title        = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_SY02QGKVB4X94AC70CRT9QZ2PE},\n  note         = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGF8",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGF8",
      "indicator": {
        "slug": "business-earnings-per-share",
        "name": "Business earnings per share",
        "definition": "Adjusted non-IFRS net income per share reflecting ongoing operational business performance."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2026-04-01",
        "end": "2026-06-30",
        "type": "quarter"
      },
      "value": 2.09,
      "value_text": "€2.09",
      "unit": "EUR",
      "currency": "EUR",
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "Sanofi",
        "org_short_name": "Sanofi",
        "org_url": "https://www.sanofi.com",
        "org_tier": 2,
        "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded",
        "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767",
        "document_type": "press_release",
        "locator": "Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded",
        "quote": "Q2 sales growth of 17.8% at CER1 and business earnings per share (EPS)2 of €2.09",
        "published_date": "2026-07-30",
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGF8",
        "bibtex": "@misc{sanofi2026businessbjmgf8,\n  author       = {{Sanofi}},\n  title        = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGF8},\n  note         = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    },
    {
      "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGFG",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFG",
      "indicator": {
        "slug": "business-earnings-per-share-growth",
        "name": "Business earnings per share growth",
        "definition": "Percentage growth in non-IFRS business earnings per share at reported actual exchange rates."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2026-04-01",
        "end": "2026-06-30",
        "type": "quarter"
      },
      "value": 31.4,
      "value_text": "31.4%",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "Sanofi",
        "org_short_name": "Sanofi",
        "org_url": "https://www.sanofi.com",
        "org_tier": 2,
        "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded",
        "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767",
        "document_type": "press_release",
        "locator": "Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded",
        "quote": "Business EPS was €2.09, up by 33.3% at CER; 31.4% at actual exchange rates; IFRS EPS €0.29",
        "published_date": "2026-07-30",
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFG",
        "bibtex": "@misc{sanofi2026businessbjmgfg,\n  author       = {{Sanofi}},\n  title        = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFG},\n  note         = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    },
    {
      "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNA",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNA",
      "indicator": {
        "slug": "covid-19-vaccines-and-therapeutics-spending-decline",
        "name": "COVID-19 vaccines and therapeutics spending decline",
        "definition": "Annual decline in spending on COVID-19 vaccines and antiviral therapeutics."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "US",
        "name": "United States",
        "type": "country"
      },
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "type": "year"
      },
      "value": 4,
      "value_text": "$4 billion",
      "unit": "USD",
      "currency": "USD",
      "scale": "billion",
      "value_type": "actual",
      "source": {
        "org": "IQVIA Institute",
        "org_short_name": "IQVIA",
        "org_url": "https://www.iqvia.com",
        "org_tier": 3,
        "document_title": "U.S. Medicine Use Trends 2026",
        "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026",
        "document_type": "press_release",
        "locator": "Other Findings",
        "quote": "COVID‑19 vaccines and therapeutics, which contributed to spending growth in 2024, declined by $4 billion in 2025.",
        "published_date": null,
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNA",
        "bibtex": "@misc{iqvia2025covidkt7nna,\n  author       = {{IQVIA Institute}},\n  title        = {U.S. Medicine Use Trends 2026},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNA},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    },
    {
      "id": "stat_QQG2RVEKCGHD2E7P4ZJTWKGDS9",
      "url": "https://statorigin.org/stat/stat_QQG2RVEKCGHD2E7P4ZJTWKGDS9",
      "indicator": {
        "slug": "category-1-innovative-drugs-added-to-national-health-insurance-catalog",
        "name": "Category 1 innovative drugs added to national health insurance catalog",
        "definition": "Number of category 1 innovative drugs newly added to the national health insurance drug catalog."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "CN",
        "name": "China",
        "type": "country"
      },
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "type": "year"
      },
      "value": 50,
      "value_text": "50",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "National Healthcare Security Administration",
        "org_short_name": "NHSA",
        "org_url": "https://www.nhsa.gov.cn",
        "org_tier": 1,
        "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录",
        "document_url": "https://www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html",
        "document_type": "press_release",
        "locator": "国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录",
        "quote": "经相应程序，本次目录调整新增114种药品，其中50种1类创新药，同时调出了29种临床没有供应或可被其他药物更好替代的药品（其中9种尚有相同治疗主成分的其他剂型在目录内，不减少目录编号）。",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html. Via StatOrigin, https://statorigin.org/stat/stat_QQG2RVEKCGHD2E7P4ZJTWKGDS9",
        "bibtex": "@misc{nhsa2025categorywkgds9,\n  author       = {{National Healthcare Security Administration}},\n  title        = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_QQG2RVEKCGHD2E7P4ZJTWKGDS9},\n  note         = {Original source: https://www.nhsa.gov.cn/art/2025/12/7/art\\_14\\_18972.html. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNS",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNS",
      "indicator": {
        "slug": "cell-and-gene-therapy-clinical-trial-starts",
        "name": "Cell and gene therapy clinical trial starts",
        "definition": "Number of clinical trials of cell and gene therapies started in a given period."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        },
        {
          "slug": "healthcare",
          "name": "Human health activities",
          "isic": "Q86",
          "is_primary": false
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2023-01-01",
        "end": "2023-12-31",
        "type": "year"
      },
      "value": 631,
      "value_text": "631",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "IQVIA Institute",
        "org_short_name": "IQVIA",
        "org_url": "https://www.iqvia.com",
        "org_tier": 3,
        "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios",
        "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies",
        "document_type": "press_release",
        "locator": "Cell and gene therapy clinical trial starts by type, 2013-2023",
        "quote": "Over the last five years 3,285 trials were started to evaluate cell and gene therapies in patients across all sponsor types, including 631 in 2023.",
        "published_date": null,
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNS",
        "bibtex": "@misc{iqvia2023cellkt7nns,\n  author       = {{IQVIA Institute}},\n  title        = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n  year         = {2023},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNS},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    },
    {
      "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNR",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNR",
      "indicator": {
        "slug": "cell-and-gene-therapy-clinical-trial-starts",
        "name": "Cell and gene therapy clinical trial starts",
        "definition": "Number of clinical trials of cell and gene therapies started in a given period."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        },
        {
          "slug": "healthcare",
          "name": "Human health activities",
          "isic": "Q86",
          "is_primary": false
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2019-01-01",
        "end": "2023-12-31",
        "type": "year"
      },
      "value": 3285,
      "value_text": "3,285",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "IQVIA Institute",
        "org_short_name": "IQVIA",
        "org_url": "https://www.iqvia.com",
        "org_tier": 3,
        "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios",
        "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies",
        "document_type": "press_release",
        "locator": "Cell and gene therapy clinical trial starts by type, 2013-2023",
        "quote": "Over the last five years 3,285 trials were started to evaluate cell and gene therapies in patients across all sponsor types, including 631 in 2023.",
        "published_date": null,
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNR",
        "bibtex": "@misc{iqvia2023cellkt7nnr,\n  author       = {{IQVIA Institute}},\n  title        = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n  year         = {2023},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNR},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    },
    {
      "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNZ",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNZ",
      "indicator": {
        "slug": "cell-and-gene-therapy-reimbursement-rate",
        "name": "Cell and gene therapy reimbursement rate",
        "definition": "Percentage of cell and gene therapies that are reimbursed in a given country or region."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        },
        {
          "slug": "healthcare",
          "name": "Human health activities",
          "isic": "Q86",
          "is_primary": false
        }
      ],
      "region": {
        "code": "EU",
        "name": "European Union",
        "type": "bloc"
      },
      "period": {
        "start": "2023-04-01",
        "end": "2023-04-01",
        "type": "point"
      },
      "value": 42,
      "value_text": "42%",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "IQVIA Institute",
        "org_short_name": "IQVIA",
        "org_url": "https://www.iqvia.com",
        "org_tier": 3,
        "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios",
        "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies",
        "document_type": "press_release",
        "locator": "Status of cell and gene therapy reimbursement in Europe (Apr 2023) compared to GDP per capital 2022, current international dollars PPP",
        "quote": "Within Western Europe, the wealthiest countries — Luxembourg and Switzerland — reimburse fewer therapies (42%) than Germany and France, which have lower GDP per capita but reimburse 75% or more of therapies.",
        "published_date": null,
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNZ",
        "bibtex": "@misc{iqvia2023cellkt7nnz,\n  author       = {{IQVIA Institute}},\n  title        = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n  year         = {2023},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNZ},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    },
    {
      "id": "stat_7J64CQDPE38R0DC4ACBET5KH2X",
      "url": "https://statorigin.org/stat/stat_7J64CQDPE38R0DC4ACBET5KH2X",
      "indicator": {
        "slug": "cell-and-gene-therapy-reimbursement-rate",
        "name": "Cell and gene therapy reimbursement rate",
        "definition": "Percentage of cell and gene therapies that are reimbursed in a given country or region."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "EU",
        "name": "European Union",
        "type": "bloc"
      },
      "period": {
        "start": "2023-04-01",
        "end": "2023-04-30",
        "type": "month"
      },
      "value": 42,
      "value_text": "42%",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "IQVIA Institute",
        "org_short_name": "IQVIA",
        "org_url": "https://www.iqvia.com",
        "org_tier": 3,
        "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios",
        "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies",
        "document_type": "press_release",
        "locator": "Status of cell and gene therapy reimbursement in Europe (Apr 2023) compared to GDP per capital 2022, current international dollars PPP",
        "quote": "Within Western Europe, the wealthiest countries — Luxembourg and Switzerland — reimburse fewer therapies (42%) than Germany and France, which have lower GDP per capita but reimburse 75% or more of therapies.",
        "published_date": null,
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_7J64CQDPE38R0DC4ACBET5KH2X",
        "bibtex": "@misc{iqvia2023cellt5kh2x,\n  author       = {{IQVIA Institute}},\n  title        = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n  year         = {2023},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_7J64CQDPE38R0DC4ACBET5KH2X},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNE",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNE",
      "indicator": {
        "slug": "cell-and-gene-therapy-share-of-medicine-spending",
        "name": "Cell and gene therapy share of medicine spending",
        "definition": "Percentage of total medicine spending attributable to cell and gene therapies."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        },
        {
          "slug": "healthcare",
          "name": "Human health activities",
          "isic": "Q86",
          "is_primary": false
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2023-01-01",
        "end": "2023-12-31",
        "type": "year"
      },
      "value": 0.4,
      "value_text": "0.4%",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "IQVIA Institute",
        "org_short_name": "IQVIA",
        "org_url": "https://www.iqvia.com",
        "org_tier": 3,
        "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios",
        "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies",
        "document_type": "press_release",
        "locator": "Key findings",
        "quote": "Spending on cell and gene therapies is increasing rapidly and reached $5.9Bn in 2023, up 38% from 2022 although spending accounted for only 0.4% of the $1.6Tn spent on medicines globally in 2023.",
        "published_date": null,
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNE",
        "bibtex": "@misc{iqvia2023cellkt7nne,\n  author       = {{IQVIA Institute}},\n  title        = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n  year         = {2023},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNE},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    },
    {
      "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNT",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNT",
      "indicator": {
        "slug": "cell-and-gene-therapy-spending",
        "name": "Cell and gene therapy spending",
        "definition": "Total spending on cell and gene therapies in a given year."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        },
        {
          "slug": "healthcare",
          "name": "Human health activities",
          "isic": "Q86",
          "is_primary": false
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2023-01-01",
        "end": "2023-12-31",
        "type": "year"
      },
      "value": 5.9,
      "value_text": "$5.9Bn",
      "unit": "USD",
      "currency": "USD",
      "scale": "billion",
      "value_type": "actual",
      "source": {
        "org": "IQVIA Institute",
        "org_short_name": "IQVIA",
        "org_url": "https://www.iqvia.com",
        "org_tier": 3,
        "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios",
        "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies",
        "document_type": "press_release",
        "locator": "Global cell and gene therapy spending and share by geography",
        "quote": "Global spending on these therapies reached $5.9Bn in 2023.",
        "published_date": null,
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNT",
        "bibtex": "@misc{iqvia2023cellkt7nnt,\n  author       = {{IQVIA Institute}},\n  title        = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n  year         = {2023},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNT},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    },
    {
      "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNW",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNW",
      "indicator": {
        "slug": "cell-and-gene-therapy-spending-average-annual-growth-rate",
        "name": "Cell and gene therapy spending average annual growth rate",
        "definition": "Average annual percentage growth in cell and gene therapy spending over a multi-year period."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        },
        {
          "slug": "healthcare",
          "name": "Human health activities",
          "isic": "Q86",
          "is_primary": false
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2019-01-01",
        "end": "2023-12-31",
        "type": "year"
      },
      "value": 65,
      "value_text": "65%",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "IQVIA Institute",
        "org_short_name": "IQVIA",
        "org_url": "https://www.iqvia.com",
        "org_tier": 3,
        "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios",
        "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies",
        "document_type": "press_release",
        "locator": "Global cell and gene therapy spending and share by geography",
        "quote": "Spending grew by 38% in 2023 from the prior year, and spending has averaged 65% annual growth over the last five years as more products are reaching the market.",
        "published_date": null,
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNW",
        "bibtex": "@misc{iqvia2023cellkt7nnw,\n  author       = {{IQVIA Institute}},\n  title        = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n  year         = {2023},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNW},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    },
    {
      "id": "stat_KZMQKVXHWFTKJV7T310W619CKK",
      "url": "https://statorigin.org/stat/stat_KZMQKVXHWFTKJV7T310W619CKK",
      "indicator": {
        "slug": "cell-and-gene-therapy-spending-growth-rate",
        "name": "Cell and gene therapy spending growth rate",
        "definition": "Year-over-year percentage growth in spending on cell and gene therapies."
      },
      "industry": [
        {
          "slug": "healthcare",
          "name": "Human health activities",
          "isic": "Q86",
          "is_primary": true
        },
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": false
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2023-01-01",
        "end": "2023-12-31",
        "type": "year"
      },
      "value": 38,
      "value_text": "38%",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "IQVIA Institute",
        "org_short_name": "IQVIA",
        "org_url": "https://www.iqvia.com",
        "org_tier": 3,
        "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios",
        "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies",
        "document_type": "press_release",
        "locator": "Key findings",
        "quote": "Spending on cell and gene therapies is increasing rapidly and reached $5.9Bn in 2023, up 38% from 2022 although spending accounted for only 0.4% of the $1.6Tn spent on medicines globally in 2023.",
        "published_date": null,
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T01:20:11.850Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_KZMQKVXHWFTKJV7T310W619CKK",
        "bibtex": "@misc{iqvia2023cell619ckk,\n  author       = {{IQVIA Institute}},\n  title        = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n  year         = {2023},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_KZMQKVXHWFTKJV7T310W619CKK},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-17T01:20:11.850Z"
    },
    {
      "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNY",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNY",
      "indicator": {
        "slug": "cell-and-gene-therapy-spending-share-by-geography",
        "name": "Cell and gene therapy spending share by geography",
        "definition": "Percentage of cell and gene therapy spending attributable to a given geography."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2023-01-01",
        "end": "2023-12-31",
        "type": "year"
      },
      "value": 38,
      "value_text": "38%",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "IQVIA Institute",
        "org_short_name": "IQVIA",
        "org_url": "https://www.iqvia.com",
        "org_tier": 3,
        "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios",
        "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies",
        "document_type": "press_release",
        "locator": "Global cell and gene therapy spending and share by geography",
        "quote": "A majority (62%) of this spending is attributable to U.S. sales, compared to just 38% coming from other geographies.",
        "published_date": null,
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNY",
        "bibtex": "@misc{iqvia2023cellkt7nny,\n  author       = {{IQVIA Institute}},\n  title        = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n  year         = {2023},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNY},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    },
    {
      "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNX",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNX",
      "indicator": {
        "slug": "cell-and-gene-therapy-spending-share-by-geography",
        "name": "Cell and gene therapy spending share by geography",
        "definition": "Percentage of cell and gene therapy spending attributable to a given geography."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "US",
        "name": "United States",
        "type": "country"
      },
      "period": {
        "start": "2023-01-01",
        "end": "2023-12-31",
        "type": "year"
      },
      "value": 62,
      "value_text": "62%",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "IQVIA Institute",
        "org_short_name": "IQVIA",
        "org_url": "https://www.iqvia.com",
        "org_tier": 3,
        "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios",
        "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies",
        "document_type": "press_release",
        "locator": "Global cell and gene therapy spending and share by geography",
        "quote": "A majority (62%) of this spending is attributable to U.S. sales, compared to just 38% coming from other geographies.",
        "published_date": null,
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNX",
        "bibtex": "@misc{iqvia2023cellkt7nnx,\n  author       = {{IQVIA Institute}},\n  title        = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n  year         = {2023},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNX},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    },
    {
      "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNV",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNV",
      "indicator": {
        "slug": "cell-and-gene-therapy-spending-year-over-year-growth",
        "name": "Cell and gene therapy spending year-over-year growth",
        "definition": "Percentage growth in cell and gene therapy spending versus the prior year."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2023-01-01",
        "end": "2023-12-31",
        "type": "year"
      },
      "value": 38,
      "value_text": "38%",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "IQVIA Institute",
        "org_short_name": "IQVIA",
        "org_url": "https://www.iqvia.com",
        "org_tier": 3,
        "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios",
        "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies",
        "document_type": "press_release",
        "locator": "Global cell and gene therapy spending and share by geography",
        "quote": "Spending grew by 38% in 2023 from the prior year, and spending has averaged 65% annual growth over the last five years as more products are reaching the market.",
        "published_date": null,
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNV",
        "bibtex": "@misc{iqvia2023cellkt7nnv,\n  author       = {{IQVIA Institute}},\n  title        = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n  year         = {2023},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNV},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    },
    {
      "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNG",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNG",
      "indicator": {
        "slug": "cell-and-gene-therapy-venture-capital-and-public-funding-deal-count",
        "name": "Cell and gene therapy venture capital and public funding deal count",
        "definition": "Number of venture capital and public funding transactions for cell and gene therapies in a given year."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        },
        {
          "slug": "healthcare",
          "name": "Human health activities",
          "isic": "Q86",
          "is_primary": false
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2023-01-01",
        "end": "2023-12-31",
        "type": "year"
      },
      "value": 100,
      "value_text": "nearly 100 deals",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "estimate",
      "source": {
        "org": "IQVIA Institute",
        "org_short_name": "IQVIA",
        "org_url": "https://www.iqvia.com",
        "org_tier": 3,
        "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios",
        "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies",
        "document_type": "press_release",
        "locator": "Cell and gene therapy venture capital and public funding deal value in U.S.$$Mn and number of deals by type, 2014-2023",
        "quote": "Following historic funding levels in 2021 and a retraction in 2022, nearly 100 deals and $3.4Bn of deal value occurred in 2023.",
        "published_date": null,
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNG",
        "bibtex": "@misc{iqvia2023cellkt7nng,\n  author       = {{IQVIA Institute}},\n  title        = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n  year         = {2023},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNG},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    },
    {
      "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNP",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNP",
      "indicator": {
        "slug": "cell-and-gene-therapy-venture-capital-and-public-funding-deal-count",
        "name": "Cell and gene therapy venture capital and public funding deal count",
        "definition": "Number of venture capital and public funding transactions for cell and gene therapies in a given year."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        },
        {
          "slug": "healthcare",
          "name": "Human health activities",
          "isic": "Q86",
          "is_primary": false
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2023-01-01",
        "end": "2023-12-31",
        "type": "year"
      },
      "value": 96,
      "value_text": "96 deals",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "IQVIA Institute",
        "org_short_name": "IQVIA",
        "org_url": "https://www.iqvia.com",
        "org_tier": 3,
        "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios",
        "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies",
        "document_type": "press_release",
        "locator": "Cell and gene therapy venture capital and public funding deal value in U.S.$$Mn and number of deals by type, 2014-2023",
        "quote": "The total number of deals peaked at 127 in 2021 — 57% higher than in 2020 — dropped 24% in 2022 to 97 deals, and remained flat in 2023 at 96 deals, although still up 19% from 2020.",
        "published_date": null,
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNP",
        "bibtex": "@misc{iqvia2023cellkt7nnp,\n  author       = {{IQVIA Institute}},\n  title        = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n  year         = {2023},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNP},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    },
    {
      "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNN",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNN",
      "indicator": {
        "slug": "cell-and-gene-therapy-venture-capital-and-public-funding-deal-count",
        "name": "Cell and gene therapy venture capital and public funding deal count",
        "definition": "Number of venture capital and public funding transactions for cell and gene therapies in a given year."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        },
        {
          "slug": "healthcare",
          "name": "Human health activities",
          "isic": "Q86",
          "is_primary": false
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2022-01-01",
        "end": "2022-12-31",
        "type": "year"
      },
      "value": 97,
      "value_text": "97 deals",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "IQVIA Institute",
        "org_short_name": "IQVIA",
        "org_url": "https://www.iqvia.com",
        "org_tier": 3,
        "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios",
        "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies",
        "document_type": "press_release",
        "locator": "Cell and gene therapy venture capital and public funding deal value in U.S.$$Mn and number of deals by type, 2014-2023",
        "quote": "The total number of deals peaked at 127 in 2021 — 57% higher than in 2020 — dropped 24% in 2022 to 97 deals, and remained flat in 2023 at 96 deals, although still up 19% from 2020.",
        "published_date": null,
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "IQVIA Institute. (2022). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNN",
        "bibtex": "@misc{iqvia2022cellkt7nnn,\n  author       = {{IQVIA Institute}},\n  title        = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n  year         = {2022},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNN},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    },
    {
      "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNJ",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNJ",
      "indicator": {
        "slug": "cell-and-gene-therapy-venture-capital-and-public-funding-deal-count",
        "name": "Cell and gene therapy venture capital and public funding deal count",
        "definition": "Number of venture capital and public funding transactions for cell and gene therapies in a given year."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        },
        {
          "slug": "healthcare",
          "name": "Human health activities",
          "isic": "Q86",
          "is_primary": false
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2021-01-01",
        "end": "2021-12-31",
        "type": "year"
      },
      "value": 127,
      "value_text": "127",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "IQVIA Institute",
        "org_short_name": "IQVIA",
        "org_url": "https://www.iqvia.com",
        "org_tier": 3,
        "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios",
        "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies",
        "document_type": "press_release",
        "locator": "Cell and gene therapy venture capital and public funding deal value in U.S.$$Mn and number of deals by type, 2014-2023",
        "quote": "The total number of deals peaked at 127 in 2021 — 57% higher than in 2020 — dropped 24% in 2022 to 97 deals, and remained flat in 2023 at 96 deals, although still up 19% from 2020.",
        "published_date": null,
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "IQVIA Institute. (2021). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNJ",
        "bibtex": "@misc{iqvia2021cellkt7nnj,\n  author       = {{IQVIA Institute}},\n  title        = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n  year         = {2021},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNJ},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    },
    {
      "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNH",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNH",
      "indicator": {
        "slug": "cell-and-gene-therapy-venture-capital-and-public-funding-deal-value",
        "name": "Cell and gene therapy venture capital and public funding deal value",
        "definition": "Total value of venture capital and public funding transactions for cell and gene therapies in a given year."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        },
        {
          "slug": "healthcare",
          "name": "Human health activities",
          "isic": "Q86",
          "is_primary": false
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2023-01-01",
        "end": "2023-12-31",
        "type": "year"
      },
      "value": 3.4,
      "value_text": "$3.4Bn",
      "unit": "USD",
      "currency": "USD",
      "scale": "billion",
      "value_type": "actual",
      "source": {
        "org": "IQVIA Institute",
        "org_short_name": "IQVIA",
        "org_url": "https://www.iqvia.com",
        "org_tier": 3,
        "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios",
        "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies",
        "document_type": "press_release",
        "locator": "Cell and gene therapy venture capital and public funding deal value in U.S.$$Mn and number of deals by type, 2014-2023",
        "quote": "Following historic funding levels in 2021 and a retraction in 2022, nearly 100 deals and $3.4Bn of deal value occurred in 2023.",
        "published_date": null,
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNH",
        "bibtex": "@misc{iqvia2023cellkt7nnh,\n  author       = {{IQVIA Institute}},\n  title        = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n  year         = {2023},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNH},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    },
    {
      "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNQ",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNQ",
      "indicator": {
        "slug": "cell-and-gene-therapy-venture-funding-deal-count-year-over-year-change",
        "name": "Cell and gene therapy venture funding deal count year-over-year change",
        "definition": "Percentage change in the number of cell and gene therapy venture capital and public funding deals versus the prior year."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2023-01-01",
        "end": "2023-12-31",
        "type": "year"
      },
      "value": 19,
      "value_text": "19%",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "IQVIA Institute",
        "org_short_name": "IQVIA",
        "org_url": "https://www.iqvia.com",
        "org_tier": 3,
        "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios",
        "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies",
        "document_type": "press_release",
        "locator": "Cell and gene therapy venture capital and public funding deal value in U.S.$$Mn and number of deals by type, 2014-2023",
        "quote": "The total number of deals peaked at 127 in 2021 — 57% higher than in 2020 — dropped 24% in 2022 to 97 deals, and remained flat in 2023 at 96 deals, although still up 19% from 2020.",
        "published_date": null,
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNQ",
        "bibtex": "@misc{iqvia2023cellkt7nnq,\n  author       = {{IQVIA Institute}},\n  title        = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n  year         = {2023},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNQ},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    },
    {
      "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNM",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNM",
      "indicator": {
        "slug": "cell-and-gene-therapy-venture-funding-deal-count-year-over-year-change",
        "name": "Cell and gene therapy venture funding deal count year-over-year change",
        "definition": "Percentage change in the number of cell and gene therapy venture capital and public funding deals versus the prior year."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2022-01-01",
        "end": "2022-12-31",
        "type": "year"
      },
      "value": -24,
      "value_text": "24%",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "IQVIA Institute",
        "org_short_name": "IQVIA",
        "org_url": "https://www.iqvia.com",
        "org_tier": 3,
        "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios",
        "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies",
        "document_type": "press_release",
        "locator": "Cell and gene therapy venture capital and public funding deal value in U.S.$$Mn and number of deals by type, 2014-2023",
        "quote": "The total number of deals peaked at 127 in 2021 — 57% higher than in 2020 — dropped 24% in 2022 to 97 deals, and remained flat in 2023 at 96 deals, although still up 19% from 2020.",
        "published_date": null,
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "IQVIA Institute. (2022). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNM",
        "bibtex": "@misc{iqvia2022cellkt7nnm,\n  author       = {{IQVIA Institute}},\n  title        = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n  year         = {2022},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNM},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    },
    {
      "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNK",
      "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNK",
      "indicator": {
        "slug": "cell-and-gene-therapy-venture-funding-deal-count-year-over-year-change",
        "name": "Cell and gene therapy venture funding deal count year-over-year change",
        "definition": "Percentage change in the number of cell and gene therapy venture capital and public funding deals versus the prior year."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "GLOBAL",
        "name": "Global",
        "type": "world"
      },
      "period": {
        "start": "2021-01-01",
        "end": "2021-12-31",
        "type": "year"
      },
      "value": 57,
      "value_text": "57%",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "IQVIA Institute",
        "org_short_name": "IQVIA",
        "org_url": "https://www.iqvia.com",
        "org_tier": 3,
        "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios",
        "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies",
        "document_type": "press_release",
        "locator": "Cell and gene therapy venture capital and public funding deal value in U.S.$$Mn and number of deals by type, 2014-2023",
        "quote": "The total number of deals peaked at 127 in 2021 — 57% higher than in 2020 — dropped 24% in 2022 to 97 deals, and remained flat in 2023 at 96 deals, although still up 19% from 2020.",
        "published_date": null,
        "accessed_at": "2026-09-15",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-15T22:15:46.809Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "IQVIA Institute. (2021). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNK",
        "bibtex": "@misc{iqvia2021cellkt7nnk,\n  author       = {{IQVIA Institute}},\n  title        = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n  year         = {2021},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNK},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}"
      },
      "updated_at": "2026-09-15T22:15:46.809Z"
    }
  ],
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 534,
    "limit": 50,
    "next_cursor": "eyJvIjo1MH0="
  }
}